Until recently, limited options were available in acute myeloid leukemia (AML). The approval of 8 new agents or formulations in the last 2 years has caused a paradigm shift in AML management, centered on incorporation of targeted agents interrupting key dysregulated enzymes. This interactive infographic focuses on the FLT3 mutation, its clinical implications, testing strategies, and the safety/efficacy of new and emerging FLT3 inhibitors.
Upon successful completion of this education activity, participants should be better able to:
Harvard Medical School
Associate Physician, Medicine
Brigham and Women’s Hospital
Clinical Director, Adult Leukemia Program
Dana-Farber Cancer Institute